The Brief

WASHINGTON - President Donald Trump announced a deal on Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices on popular obesity drugs.

The obsesity treatements Zepbound and Wegovy are part of a new generation of obsesity medications known as GLP-1 receptor agonists.

Trump reveals deal with drugmakers to lower obesity drug costs

What they're saying:

Trump made the announcement in the Oval Office with drugmakers, calling it a "triumph for American patients that will save lives and improve the health of millions and millions of Americans."

What we know:

Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients wit

See Full Page